As of 2026-03-18, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is -5.12. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is 218.15 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-13 | -5.71 |
| 2026-03-12 | -6.07 |
| 2026-03-11 | -7.53 |
| 2026-03-10 | -6.01 |
| 2026-03-09 | -5.30 |
| 2026-03-06 | -5.67 |
| 2026-03-05 | -5.61 |
| 2026-03-04 | -7.11 |
| 2026-03-03 | -7.22 |
| 2026-03-02 | -8.02 |
| 2026-02-27 | -7.85 |
| 2026-02-26 | -7.85 |
| 2026-02-25 | -8.36 |
| 2026-02-24 | -8.50 |
| 2026-02-23 | -7.86 |
| 2026-02-20 | -7.85 |
| 2026-02-19 | -8.37 |
| 2026-02-18 | -7.85 |
| 2026-02-17 | -8.23 |
| 2026-02-13 | -8.42 |
| 2026-02-12 | -7.49 |
| 2026-02-11 | -8.27 |
| 2026-02-10 | -8.87 |
| 2026-02-09 | -8.60 |
| 2026-02-06 | -9.13 |
| 2026-02-05 | -8.26 |
| 2026-02-04 | -9.15 |
| 2026-02-03 | -9.78 |
| 2026-02-02 | -11.00 |
| 2026-01-30 | -11.06 |
| 2026-01-29 | -11.27 |
| 2026-01-28 | -12.11 |
| 2026-01-27 | -12.42 |
| 2026-01-26 | -12.16 |
| 2026-01-23 | -12.66 |
| 2026-01-22 | -12.34 |
| 2026-01-21 | -12.61 |
| 2026-01-20 | -12.61 |
| 2026-01-16 | -14.15 |
| 2026-01-15 | -12.57 |
| 2026-01-14 | -13.25 |
| 2026-01-13 | -12.75 |
| 2026-01-12 | -13.41 |
| 2026-01-09 | -13.22 |
| 2026-01-08 | -13.60 |
| 2026-01-07 | -13.94 |
| 2026-01-06 | -13.80 |
| 2026-01-05 | -12.89 |
| 2026-01-02 | -13.00 |
| 2025-12-31 | -11.61 |